Top-Ranked Analysts Are Bullish On Gilead Sciences, Inc.
May 14, 2015 at 12:21 PM EDT
Gilead Sciences has been a favorite among biotech investors due to its successful hepatitis C therapies; Harvoni and Sovaldi. However, the biopharmaceutical company is making headlines again with a new drug for gastric cancer; GS-5745.
